Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Samjin Pharmaceutical Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary artery disease after percutaneous coronary intervention with the newer drug-eluting stent.
With the development of the newer generation drug-eluting stents, percutaneous coronary intervention (PCI) has been a feasible treatment for patient with coronary artery disease. However, stent failures including in-stent restenosis and stent thrombosis have been still problematic. Moreover, neoatherosclerosis, which is the atherosclerotic process developed in the neointima within the implanted stent, has been reported to be associated with neoatherosclerotic plaque rupture and contribute to the development of acute coronary syndrome in patients after drug-eluting stent (DES) implantation.
In this perspective, recent AHA/ACC and ESC guidelines recommend the high-dose(intensity) statin therapy for patients performed PCI. However, the efficacy of the high-dose(intensity) statin therapy on cardiovascular outcomes is still controversial. Several meta-analysis failed to show the benefit of the high-dose(intensity) statin therapy to reduce the mortality. Moreover, clear evidence for the benefits of such high-dose(intensity) statin therapy has no yet been demonstrated in East Asian patients.
This trial was designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary artery disease after PCI in the era of the newer generation DES era.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Rosuvastatin 5mg | Experimental | Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention |
|
| Rosuvastatin 20mg | Active Comparator | Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rosuvastatin 5mg | Drug | Rosuvastatin 5mg tablet, q.d., for 30 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Major adverse cardiovascular outcome | The cumulative incidences of the composite events of cardiac death, myocardial infarction, and repeat revascularization | Baseline to Final visit (30 months) |
| Measure | Description | Time Frame |
|---|---|---|
| All-cause death | The cumulative incidences of all-cause death for 30 months after percutaneous coronary intervention with drug-eluting stent | Baseline to Final visit (30 months) |
| Cardiac death |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hyung Joon Joo, MD, PhD | Contact | +8229205445 | drjoohj@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Hyung Joon Joo, MD, PhD | Department of Cardiology, Korea University Anam Hospital | Principal Investigator |
| Do-sun Lim, MD, PhD | Department of Cardiology, Korea University Anam Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Korea University Anam Hospital | Recruiting | Seoul | 02841 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D003327 | Coronary Disease |
| D002318 | Cardiovascular Diseases |
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068718 | Rosuvastatin Calcium |
| D044382 | Population Groups |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D005464 | Fluorobenzenes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Rosuvastatin 20mg | Drug | Rosuvastatin 5mg tablet, q.d., for 30 months |
|
|
The cumulative incidences of cardiac death for 30 months after percutaneous coronary intervention with drug-eluting stent
| Baseline to Final visit (30 months) |
| Non-fatal myocardial infarction | The cumulative incidences of non-fatal myocardial infarction for 30 months after percutaneous coronary intervention with drug-eluting stent | Baseline to Final visit (30 months) |
| Repeat revascularization | The cumulative incidences of any repeat coronary revascularization for 30 months after percutaneous coronary intervention with drug-eluting stent | Baseline to Final visit (30 months) |
| Stent thrombosis | The cumulative incidences of stent thrombosis categorized by ARC criteria for 30 months after percutaneous coronary intervention with drug-eluting stent | Baseline to Final visit (30 months) |
| Target LDL-C level achievement | The percentage of the participants who reached the LDL-C level of <70mg/dL after the treatment for 6 months. | 6 months of treatment and thereafter |
| LDL-C level change | The percent changes of LDL-C level from baseline to to 6 months of treatment and thereafter | Baseline to 6 months of treatment and thereafter |
| HDL-C level change | The percent changes of HDL-C level from baseline to to 6 months of treatment and thereafter | Baseline to 6 months of treatment and thereafter |
| Level change of other biomarkers | The percent changes of serum level of other biomarkers from baseline to to 6 months of treatment and thereafter | Baseline to 6 months of treatment and thereafter |
| D014652 |
| Vascular Diseases |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006845 |
| Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D003710 | Demography |
| D011154 | Population Characteristics |